Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis. Issue 50 (8th December 2021)

• Record Type: Journal Article
• Authors: Muhi, Stephen; Stinear, Timothy P.
• Is Part Of: Vaccine. Volume 39:Issue 50(2021)
• Page Start: 7238
• Page End: 7252
• Publication Date: 2021-12-08
• Subjects: Buruli ulcer -- Mycobacterium ulcerans -- BCG -- Vaccine -- Mycolactone; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.05.092
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Buruli ulcer, caused by Mycobacterium ulcerans, is a neglected tropical disease endemic to over 30 countries, with increasing incidence in temperate, coastal Victoria, Australia. Strategies to control transmission are urgently required. This study systematically reviews the literature to identify and describe candidate prophylactic Buruli ulcer vaccines. This review highlights that Mycobacterium bovis Bacillus Calmette-Guérin (BCG) vaccine is the only vaccine studied in randomised controlled trials and confirms its importance as a benchmark for comparison against putative vaccines in pre-clinical studies. Nevertheless, BCG alone is unable to offer long-term protection in humans. A number of experimental vaccines that exceed the protection provided by BCG in mice have emerged, particularly those utilising recombinant BCG expressing immunogenic M. ulcerans proteins. Although progress is promising, there remain key questions about the optimal approach to characterising the immunological correlates of protection in humans and strategies to investigate the safety and efficacy of such vaccines in humans.